Go To Global Site
Welcome to UCB in the United States

Mar

22

Press Release: CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

 

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

The_Secret_World_Inside_you_1280x960

Mar

06

UCB Sponsors New Exhibit at Atlanta’s Fernbank Museum

UCB is dedicated to supporting STEM education in the communities where we work and live. As part of this commitment, UCB is a proud sponsor of the new special exhibit, “The Secret World Inside You,” at Atlanta’s Fernbank Museum of Natural History.

new_AAD_2018_Curtain_Raiser__1280

Feb

16

Press Release: New Data Presented at 2018 AAD Annual Meeting

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018).

n_1280x960_AMSUS_171130_180659_PK_017

Feb

05

UCB Becomes Member of AMSUS Executive Advisory Board

Last year, UCB was invited to become a member of the Association of Military Surgeons of the United States (AMSUS) Executive Advisory Board as the only pharmaceutical industry representative.

Ben_Morrison_Photo_Formatted

Feb

01

My 20-Year Crohn’s-versary

Ben Morrison—comedian and Crohn’s Advocate—speaks candidly about his experience living with Crohn’s disease. He shares personal insights on the progress of Crohn’s care and the availability of information over the last 20 years.

1280x_960_UCB_B1_NavigatingInsurance_618963716_1280x550

Jan

18

Insurance Tips and Resources for Managing your Plan

It’s that time of the year again. Open enrollment for insurance has closed, and it is time to start using your new 2018 plans. Sometimes, understanding your health coverage and planning for your healthcare needs can be challenging.

crop_MG_5680_cropped

Jan

12

Case Study: The Right Patients at the Right Time

Following a recent review of Tussionex® (hydrocodone polistirex and chlorpheniramine polistirex) – a cough syrup containing hydrocodone and chlorpheniramine– we determined the benefit-risk balance for the use of Tussionex® to treat cough associated with cold or allergy in children was no longer favorable. Because of this, UCB proactively approached the U.S. Food and Drug Administration (FDA) to request that Tussionex® be limited to use in adults.